Find information on thousands of medical conditions and prescription drugs.

Vitrase

The hyaluronidases (EC 3.2.1.35) are a family of enzymes that degrade hyaluronic acid.

The enzyme increases tissue permeability, and consequently is used in conjunction with other drugs, to speed their dispersion and delivery. The most common example is opthalmic surgery, where it is used in combination with local anesthetics.

Some bacteria produce hyaluronidase.

In human fertilization, hyaluronidase is released by the acrosome of the sperm cell after it has reached the oocyte. Hyaluronidase aids in digesting proteins in the zona pellucida, thus enabling conception.

Brand names include Vitrase® (ISTA Pharmaceuticals) and Wydase®.

Home

Vagifem

Valcyte

Valine

Valium

Valstar

Valtrex

Vaniqa

Velcade

Velivet

Venlafaxine

Ventolin

Vepesid

Verapamil

Verelan

Vermox

Versed

Vfend

Viadur

Viagra

Vicoprofen

Vidarabine

Vidaza

Videx

Vioxx

Viread

Visine

Vistide

Visudyne

Vitaped

Vitrase

Vivelle

Volmax

Voltaren

Voriconazole

Vosol

Read more at Wikipedia.org

• [List your site here Free!]


		Ista Pharmaceuticals, Inc. [dagger]: FDA Advisory Committee to consider ISTA Pharmaceuticals' Vitrase(R) on March 17, 2003. (Equities reporter: Advertising). : An article from: Equities $5.95


	ISTA Pharmaceuticals Announces Phase III Data Demonstrating that a Single Intravitreous Injection of VITRASE® Results in Improved Visual Acuity Findings Presented in Poster Session during 109th American Academy of Ophthalmology Annual Meeting in Chicago, Illinois IRVINE, Calif., Oct. 20 /PRNewswire-FirstCall/ ... From PR Newswire, 10/20/05

	ISTA Pharmaceuticals Announces VITRASE® Spreading Agent and Adjunct Clinical Data Presentations for Fall 2005 IRVINE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. today announced its Fall 2005 schedule for presenting clinical data on its product, Vitrase(R) (Ovine Hyaluronidase), From PR Newswire, 9/19/05

	ISTA Pharmaceuticals Announces Date for Release of Phase III Clinical Trial Results of Vitrase for the Treatment of Severe Vitreous Hemorrhage Medical & Health Writers IRVINE, Calif.--(BW HealthWire)--Dec. 10, 2001 ISTA Pharmaceuticals(TM), Inc. (Nasdaq: ISTA), today announced that on January ... From Business Wire, 12/10/01

	Advanced Corneal Systems Begins North American Phase III Study of Vitrase, a Novel Nonsurgical Treatment for Vitreous Hemorrhage IRVINE, Calif.--(BW HealthWire)--Nov. 23, 1998--Advanced Corneal Systems, Inc. (ACS) today announced today that the company has initiated a Phase III ... From Business Wire, 11/23/98

	Advanced Corneal Systems' Vitrase for Treatment of Vitreous Hemorrhage Receives FDA Fast Track Designation IRVINE, Calif.--(BW HealthWire)--Oct. 15, 1998--Advanced Corneal Systems, Inc. (ACS) today announced that the company's investigational drug Vitrase(tm), ... From Business Wire, 10/15/98

	Phase III Clinical Trial Results Support Ability of Vitrase to Safely and Effectively Clear Vitreous Hemorrhage IRVINE, Calif.--(BW HealthWire)--June 25, 1998--Advanced Corneal Systems, Inc. ("ACS") announced that clinical data presented at the 28th International ... From Business Wire, 6/25/98

	Advanced Corneal Systems Files for Vitrase Approval in Mexico IRVINE, Calif.--(BW HealthWire)--June 2, 1998--Advanced Corneal Systems, Inc. (ACS) today announced that its Registration Submission for Pharmaceutical ... From Business Wire, 6/2/98

	ISTA Pharmaceuticals Reports Third Quarter 2005 Financial Results IRVINE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. today reported its unaudited financial results for the third quarter ended ... From PR Newswire, 11/8/05

Home

Contact

Resources

Exchange Links

ebay